Appendix Table 2.

Impact of Part D Coverage Restrictions for Antidepressants, Antipsychotics, and Cholinesterase Inhibitors on Nursing Home Resident Outcomes, 2006–2008 (UNADJUSTED RESULTS)

	OUTCOME MEASURES
CLASS	Depression Rating Scale (p-value) [CI]	Hallucinations or Delusions Odds Ratio (p-value) [CI]	Aggressive Behavior Scale (p-value) [CI]	Cognitive Performance Scale (p-value) [CI]	Activities of Daily Living Limitations (p-value) [CI]
Antidepressants (n= 70,662)	0.06 (0.004) [0.02 to 0.11]	1.00 (0.98) [0.90 to 1.10]	−0.03 (0.16) [−0.06 to 0.01]	−0.05 (0.02) [−0.09 to −0.01]	0.18 (0.10) [−0.03 to 0.38]
Antipsychotics (n= 43,578)	0.00 (0.86) [−0.05 to 0.06]	0.99 (0.86) [0.90 to 1.08]	−0.04 (0.17) [−0.08 to 0.01]	−0.04 (0.07) [−0.08 to 0.00]	−0.22 (0.06) [−0.45 to −0.01]
Cholinesterase Inhibitors (n= 38,199)	0.05 (0.04) [0.00 to 0.10]	1.10 (0.05) [1.00 to 1.21]	0.05 (0.04) [0.00 to 0.09]	0.04 (0.06) [−0.00 to 0.08]	−0.23 (0.06) [−0.46 to 0.01]

Note: Regression coefficients denote the impact of PDP coverage restrictions on the measures of interest, comparing residents randomized to PDPs with coverage restrictions to those who were randomized to plans with no such restrictions. We use linear regression for the MDS scales of interest (for depression, aggressive behavior, cognitive performance, and ADLs) and present results based on mean resident scores during the calendar year. We use logistic regression for the presence of hallucinations or delusions at any point over the same time period and present odds ratios of the likelihood of event occurrence. After correcting for multiple comparisons using the Bonferroni correction, none of the statistically significant results remained significant, as the threshold for significance at the 0.05 level was 0.0033.